SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Siga Technologies Inc. (SIGA) closed at $6.60 in the latest trading session, marking a +0.92% move from the prior day.

Siga Technologies Inc. (SIGA) Increases Despite Market Slip: Here's What You Need to Know

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by SIGA Technologies, Inc.

Drugmaker Siga Technologies said on Tuesday it would supply its therapy for mpox in Morocco, in response to a request from the country's health ministry for protection against any potential outbreak of the disease.

Siga Technologies to supply mpox therapy in Morocco

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

ATTENTION SIGA SHAREHOLDERS: Investors who Lost Money on SIGA Technologies, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) --  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak.

SIGA Announces Agreement to Supply TPOXX® in Morocco

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of SIGA stockholders. Our investigation concerns whether SIGA has violated the federal securities laws and/or engaged in other unlawful business practices.

SIGA ALERT: Bragar Eagel & Squire, P.C. is Investigating SIGA Technologies, Inc. on Behalf of SIGA Stockholders and Encourages Investors to Contact the Firm

Siga Technologies Inc. (SIGA) closed at $6.99 in the latest trading session, marking a +0.36% move from the prior day.

Siga Technologies Inc. (SIGA) Ascends But Remains Behind Market: Some Facts to Note

Siga Technologies Inc. (SIGA) concluded the recent trading session at $6.96, signifying a +0.58% move from its prior day's close.

Siga Technologies Inc. (SIGA) Advances While Market Declines: Some Information for Investors

NEW YORK--(BUSINESS WIRE)---- $SIGA #INVESTOR--The law firm of Kirby McInerney LLP is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA). The investigation concerns whether SIGA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On September 23, 2024, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varm.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against SIGA Technologies, Inc. (SIGA)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your SIGA investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities law.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of SIGA Technologies, Inc. (SIGA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) investors concerning the Company's possible violations of federal securities laws. On September 23, 2024, after market hours, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position. On this news, SIGA's stock price fell $0.42, or 5%, to close at $8.01 per s.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of SIGA Technologies, Inc. (SIGA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 23, 2024, after market hours, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position.

The Law Offices of Frank R. Cruz Announces Investigation of SIGA Technologies, Inc. (SIGA) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by SIGA Technologies, Inc. (SIGA)

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

Levi & Korsinsky Announces an Investigation on Behalf of SIGA Technologies, Inc. (SIGA) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA Technologies, Inc. (SIGA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA Technologies, Inc. Being Investigated on Behalf of SIGA Technologies, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc. (NASDAQ:SIGA) ("SIGA" or the "Company") SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.

Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating SIGA Technologies, Inc. for Potential Violations of Federal Securities Laws

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA Technologies, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by SIGA Technologies, Inc. (SIGA)

In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $8.43, denoting no change from the preceding trading day.

Siga Technologies Inc. (SIGA) Flat As Market Gains: What You Should Know

In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $7.51, indicating a -0.53% shift from the previous trading day.

Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past three years.

SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

So-called “bull traps” often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc SIGA — and there may be another one today.

Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study

SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients failed to meet its primary endpoint but showed safety. SIGA's reliance on US government contracts, especially for TPOXX, introduces substantial revenue concentration risk.

SIGA Technologies: Poised For A Potential Windfall From Monkeypox Emergency Declaration

Emergent BioSolutions

Geovax Labs

The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to spread across countries in Africa and possibly outside the continent.

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced topline results from a preliminary analysis of the PALM 007 (Tecovirimat for Treatment of Monkeypox Virus) clinical trial (NCT05559099). NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo (DRC) with monkeypox (mpox), who were administered SIGA's tecovirimat, a highly targeted antiviral treatment, versus placebo. All patients in this study were hospitalized for the entire duration of treatment. This study was not a registration study conducted under an U.S. FDA Investigational New Drug Application.

News for SIGA Technologies Stock (SIGA)